Ensuring Public Trust in an Empowered FDA

Interview with Dr. Joseph Ross on shifts in the FDA's use of accelerated approval and associated challenges for clinicians and patients. (12:17)Download The FDA's recent approval of lecanemab for Alzheimer's disease has been clouded by controversy over other accelerated approvals, illustrating challenges faced by the agency.